Clinical Trials Logo

Lung Adenocarcinoma Stage III clinical trials

View clinical trials related to Lung Adenocarcinoma Stage III.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05503667 Recruiting - EGFR Gene Mutation Clinical Trials

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.